PURPOSE: Mucin expression is a common feature of most adenocarcinomas and features prominently in current attempts to improve diagnosis and therapy for pancreatic cancer and other adenocarcinomas. We investigated the expression of a number of mucin core proteins and associated O-linked glycans expressed in pancreatic adenocarcinoma-sialyl Tn (STn), Tn, T antigen, sialyl Lewis A (CA19-9), sialyl Lewis C (SLeC), Lewis X (LeX), and sialyl LeX (SLeX)-during the progression of pancreatic cancer from early stages to metastatic disease. EXPERIMENTAL DESIGN: Immunohistochemical analyses of mucin and associated glycan expression on primary tumor and liver metastatic tumor samples were conducted with matched sets of tissues from 40 autopsy patients diagnosed with pancreatic adenocarcinoma, 14 surgically resected tissue samples, and 8 normal pancreata. RESULTS: There were significant changes in mucin expression patterns throughout disease progression. MUC1 and MUC4 were differentially glycosylated as the disease progressed from early pancreatic intraepithelial neoplasias to metastatic disease. De novo expression of several mucins correlated with increased metastasis indicating a potentially more invasive phenotype, and we show the expression of MUC6 in acinar cells undergoing acinar to ductal metaplasia. A "cancer field-effect" that included changes in mucin protein expression and glycosylation in the adjacent normal pancreas was also seen. CONCLUSIONS: There are significant alterations in mucin expression and posttranslational processing during progression of pancreatic cancer from early lesions to metastasis. The results are presented in the context of how mucins influence the biology of tumor cells and their microenvironment during progression of pancreatic cancer.
PURPOSE:Mucin expression is a common feature of most adenocarcinomas and features prominently in current attempts to improve diagnosis and therapy for pancreatic cancer and other adenocarcinomas. We investigated the expression of a number of mucin core proteins and associated O-linked glycans expressed in pancreatic adenocarcinoma-sialyl Tn (STn), Tn, T antigen, sialyl Lewis A (CA19-9), sialyl Lewis C (SLeC), Lewis X (LeX), and sialyl LeX (SLeX)-during the progression of pancreatic cancer from early stages to metastatic disease. EXPERIMENTAL DESIGN: Immunohistochemical analyses of mucin and associated glycan expression on primary tumor and liver metastatic tumor samples were conducted with matched sets of tissues from 40 autopsy patients diagnosed with pancreatic adenocarcinoma, 14 surgically resected tissue samples, and 8 normal pancreata. RESULTS: There were significant changes in mucin expression patterns throughout disease progression. MUC1 and MUC4 were differentially glycosylated as the disease progressed from early pancreatic intraepithelial neoplasias to metastatic disease. De novo expression of several mucins correlated with increased metastasis indicating a potentially more invasive phenotype, and we show the expression of MUC6 in acinar cells undergoing acinar to ductal metaplasia. A "cancer field-effect" that included changes in mucin protein expression and glycosylation in the adjacent normal pancreas was also seen. CONCLUSIONS: There are significant alterations in mucin expression and posttranslational processing during progression of pancreatic cancer from early lesions to metastasis. The results are presented in the context of how mucins influence the biology of tumor cells and their microenvironment during progression of pancreatic cancer.
Authors: Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone Journal: Ann Surg Date: 2010-05 Impact factor: 12.969
Authors: Johannes W Pedersen; Ola Blixt; Eric P Bennett; Mads A Tarp; Imran Dar; Ulla Mandel; Steen S Poulsen; Anders E Pedersen; Susanne Rasmussen; Per Jess; Henrik Clausen; Hans H Wandall Journal: Int J Cancer Date: 2011-01-12 Impact factor: 7.396
Authors: Hans H Wandall; Ola Blixt; Mads A Tarp; Johannes W Pedersen; Eric P Bennett; Ulla Mandel; Govind Ragupathi; Phil O Livingston; Michael A Hollingsworth; Joyce Taylor-Papadimitriou; Joy Burchell; Henrik Clausen Journal: Cancer Res Date: 2010-02-02 Impact factor: 12.701
Authors: Jennifer A Belisle; Sachi Horibata; Gubbels A A Jennifer; Sarah Petrie; Arvinder Kapur; Sabine André; Hans-Joachim Gabius; Claudine Rancourt; Joseph Connor; James C Paulson; Manish S Patankar Journal: Mol Cancer Date: 2010-05-24 Impact factor: 27.401
Authors: Huocong Huang; Robert A Svoboda; Audrey J Lazenby; Jintana Saowapa; Nina Chaika; Ke Ding; Margaret J Wheelock; Keith R Johnson Journal: J Biol Chem Date: 2016-09-07 Impact factor: 5.157
Authors: Prakash Radhakrishnan; Sally Dabelsteen; Frey Brus Madsen; Chiara Francavilla; Katharina L Kopp; Catharina Steentoft; Sergey Y Vakhrushev; Jesper V Olsen; Lars Hansen; Eric P Bennett; Anders Woetmann; Guangliang Yin; Longyun Chen; Haiyan Song; Mads Bak; Ryan A Hlady; Staci L Peters; Rene Opavsky; Christenze Thode; Klaus Qvortrup; Katrine T-B G Schjoldager; Henrik Clausen; Michael A Hollingsworth; Hans H Wandall Journal: Proc Natl Acad Sci U S A Date: 2014-08-12 Impact factor: 11.205
Authors: Ping Wang; Byunghee Yoo; Sarah Sherman; Pinku Mukherjee; Alana Ross; Pamela Pantazopoulos; Victoria Petkova; Christian Farrar; Zdravka Medarova; Anna Moore Journal: Int J Cancer Date: 2016-04-15 Impact factor: 7.396